Home Blog of Signal Transduction Apoptosis p53

Category

Archives

Popular Post

ESKM, a novel therapeutic agent for sensitive and resistant PH+ leukemias

The mechanism of resistance to JAK2 inhibitor in myeloproliferative neoplasms patients

Effects of PARP inhibitors in BRCA gene-mutated ovarian cancer

DASATINIB; An inhibitor of Receptor Tyrosine Kinase

GP130/JAK/STAT3 signaling pathway induces multiple myeloma

p53

Role of parthenolide in paclitaxel-induced oxidative stress injury and impaired reproductive function in rat testicular tissue

564 views | Dec 28 2023

Parthenolide treatment in rats demonstrated a dose-dependent mitigation of oxidative stress-induced testicular damage caused by paclitaxel, showing promise as a potential therapeutic avenue for addressing testicular toxicity and supporting reproductive function. [Read the Full Post]

Senolytic Combination Treatment Is More Potent Than Single Drugs in Reducing Inflammatory and Senescence Burden in Cells from Painful Degenerating IVDs

212 views | Nov 09 2023

Combining the senolytic drugs o-Vanillin and RG-7112 effectively removes senescent cells, reduces inflammation and pain mediators, and inhibits neuronal sprouting, offering promise as a potential treatment for low back pain associated with intervertebral disc degeneration. [Read the Full Post]

[p53 regulates primordial follicle activation through the mTOR signaling pathway]

511 views | Oct 22 2023

This study demonstrated that p53 inhibits primordial follicle activation through the mTOR signaling pathway, thereby maintaining the reserve of primordial follicles. [Read the Full Post]

Combining ReACp53 with Carboplatin to Target High-Grade Serous Ovarian Cancers

112 views | Jul 22 2023

The combination of ReACp53 and carboplatin has shown promising synergistic effects in targeting high-grade serous ovarian carcinomas, potentially offering a new therapeutic strategy for this aggressive subtype of ovarian cancer. [Read the Full Post]

Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study

270 views | Jun 24 2023

The combination of eprenetapopt and venetoclax with azacitidine showed promising activity and an acceptable safety profile in patients with TP53-mutated acute myeloid leukemia, supporting further evaluation of this combination as a frontline treatment option. [Read the Full Post]

Therapeutic Targets in Myelodysplastic Neoplasms: Beyond Hypomethylating Agents

255 views | Jun 24 2023

This review discusses the current management strategies and promising novel targeted therapies under investigation for the treatment of high-risk myelodysplastic neoplasms (MDS), highlighting the need for alternative options due to the limitations of allogeneic hematopoietic stem cell transplantation and the challenges associated with hypomethylating agents (HMAs). [Read the Full Post]

Three dimensional models of dedifferentiated liposarcoma cell lines: scaffold-based and scaffold-free approaches

329 views | Jun 20 2023

This study aimed to establish 3D cell culture models of liposarcomas using different methods, observing distinct structural differences and demonstrating the potential of these models to provide new insights into efficacy and toxicity, serving as an important step in the pre-clinical phase prior to clinical trials. [Read the Full Post]

MI-773, a breaker of the MDM2/p53 axis, exhibits anticancer effects in neuroblastoma via downregulation of INSM1

244 views | Jun 19 2023

MI-773, a specific antagonist of MDM2, disrupts the MDM2/p53 axis, leading to suppressed proliferation, induced apoptosis, and cell cycle arrest in neuroblastoma cells, suggesting its potential as a novel treatment strategy for this pediatric malignancy. [Read the Full Post]

The inhibition of MDM2 slows cell proliferation and activates apoptosis in ADPKD cell lines

195 views | Dec 05 2022

Simone Patergnani et al. found that the targeting of MDM2 by RG7112 might represent a new therapeutic option for the treatment of ADPKD. [Read the Full Post]

FACT subunit SUPT16H associates with BRD4 and contributes to silencing of interferon signaling

135 views | Sep 28 2022

Dawei Zhou et al. demonstrated that depletion or inhibition of SUPT16H caused the remarkable activation of IFN signaling in NK cells, which promoted the NK-mediated killing of virus-infected cells in a co-culture system using human primary NK cells. [Read the Full Post]